Sort   by:  
 Page size 
UnknownThe rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials.
Not available
S-EPMC6849556 | biostudies-literature
UnknownRedefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.
Not available
S-EPMC7411283 | biostudies-literature
UnknownInsulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Not available
S-EPMC4931208 | biostudies-literature
UnknownSafety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
Not available
S-EPMC5248618 | biostudies-literature
UnknownPharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Not available
S-EPMC4773674 | biostudies-literature
UnknownThe co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Not available
S-EPMC6033009 | biostudies-literature
UnknownIDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
Not available
S-EPMC6965526 | biostudies-literature
UnknownThe relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
Not available
S-EPMC7186831 | biostudies-literature
UnknownA greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
Not available
S-EPMC7187233 | biostudies-literature
UnknownBaseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.
Not available
S-EPMC12789876 | biostudies-literature
Sort   by:  
 Page size